News
Nippon Kayaku's news releases are issued to inform our stakeholders of the latest information regarding the Company.While some news releases may contain information about pharmaceutical products (including those under development), they are intended solely for disclosure purposes to members of the media, shareholders, and investors, and are not intend provide medical advice.
- 2025/11/28
- Notice Regarding Fire Extinguishment at Asa Plant (Kawahigashi)
- 2025/11/28
-
Notice Regarding Fire Incident at Asa Plant (Kawahigashi)
- 2025/11/12
- Nippon Kayaku announces New Product Launch: IBTROZIⓇ캡슐 200mg
- 2025/09/25
- Annual update has been made to our Sustainability 바카라 사이트 추천.
- 2025/09/19
- 일본 카야쿠 announces IBTROZIⓇCapsules 200mg (taletrectinib) has been approved in Japan for patients with unresectable advanced and/or recurrentROS1-positive non-small cell lung cancer
- 2025/08/25
- Announcement of Joint Venture Establishment and Shareholders Agreement Execution
- 2025/07/09
- Nippon Kayaku Selected as a Constituent of all ESG Indices by GPIF
- 2025/06/12
- 일본 카야쿠 announces IBTROZITMapproved in the U.S. for patients with advancedROS1-positive Non-Small Cell Lung Cancer
- 2025/06/02
- Presentation of new data from pivotal phase II clinical studies of taletrectinib, a novel ROS1 inhibitor, in patients with advancedROS1-positive Non-Small Lung Cancer at ASCO 2025
- 2025/05/30
- Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC
- 2025/05/08
- Nippon Kayaku received MSCI ESG Ratings of AA for the second year
- 2025/03/03
- Nippon Kayaku announces completion of marketing authorization application of a novel ROS1 inhibitor, taletrectinib, for use in patients with advancedROS1-positive Non-Small Cell Lung Cancer in Japan
- 2025/01/07
- 일본 카야쿠 Selected as constituent of FTSE4Good Index Series, FTSE Blossom Japan Index, and FTSE Blossom Japan Sector Relative Index
- 2024/11/01
- Presentation of a global phase II clinical study of a novel ROS1 inhibitor, taletrectinib, in patients with advancedROS1-positive Non-Small Cell Lung Cancer.
- 2024/10/10
- Annual update has been made to our Sustainability 바카라 사이트 추천.
- 2024/05/08
- Received ‘AA’ for the first time in MSCI ESG Ratings
- 2023/12/15
- NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDxTMIN JAPAN
- 2023/10/19
- Updated information of sustainability
- 2023/10/18
- Trastuzumab BS for I.V. Infusion 60mg “NK”·150mg “NK” Obtained Approval for Additional Indication
- 2023/09/25
-
일본 카야쿠와 셀트리온 주장 마케팅 Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.
